Google Übersetzer
Arrowhead Pharmaceuticals Inc
About
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 24 2026
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Apr 20 2026
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Mar 28 2026
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Feb 24 2026
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Feb 5 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Recent Videos
ARWR Stock: Morgan Stanley Sees 37% Upside! 🚀 #biotechstocks
Apr 21, 2026
Sarepta’s siRNA breakout (+35%)
Mar 27, 2026
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Mar 24, 2026
Arrowhead Pharmaceuticals Q1 2026 Earnings Call
Feb 06, 2026
Financials
Revenue
$1.09 B
Market Cap
$8.55 B
P/E Ratio
38.14
EPS
1.60